Profile for Slovenia Patent: 2392565

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

US Patent Family Members and Approved Drugs for Slovenia Patent: 2392565

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Glossary

Subscribe to access the full database, or Start Trial
US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
Start Trial	Aug 14, 2026	Exelixis	COMETRIQ	cabozantinib s-malate
Start Trial	Aug 14, 2026	Exelixis Inc	CABOMETYX	cabozantinib s-malate
Start Trial	Sep 24, 2024	Exelixis Inc	CABOMETYX	cabozantinib s-malate
>US Patent Number	>US Expiration Date	>US Applicant	>US Tradename	>Generic Name

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.